PReCedeNT Trial: PRRT Plus Chemo Boosts GEP-NETs
In a groundbreaking initiative poised to reshape the therapeutic landscape for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), researchers have launched the PReCedeNT trial—a phase III randomized-controlled study...
















